Abstract
Objective To investigate the effect of medroxyprogesterone combined with clindamycin phosphate on serum tumor necrosis factor α (TNF-α) and C-reactive protein (CRP) in patients with puerperal endometritis. Methods 138 patients with puerperal endometritis admitted into our hospital from June 2015 to October 2016 were divided into control group and observation group by treatment methods, 69 cases in each group. Control group took clindamycin phosphate orally, and observation group took medroxyprogesterone and clindamycin phosphate. After 14 d’s treatment, the levels of TNF-α, CRP, clinical efficacy, hospital stay, symptoms improvement time, and adverse reactions of two groups were compared. Results The levels of TNF-α, CRP of observation group were lower than those of control group (P 0.05). Conclusions Medroxyprogesterone combined with clindamycin phosphate for patients with puerperal endometritis can effectively improve the levels of TNF-α, CRP, increase clinical efficacy, shorten symptoms improvement time and treatment time, does not increase toxic and side effect, with high safety, worthy of clinical application and promotion. Key words: Medroxyprogesterone; Clindamycin phosphate; Puerperal endometritis; Tumor necrosis factor; C-reactive protein
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
